BR112014006222A2 - esteroides vegetais e usos dos mesmos - Google Patents

esteroides vegetais e usos dos mesmos

Info

Publication number
BR112014006222A2
BR112014006222A2 BR112014006222A BR112014006222A BR112014006222A2 BR 112014006222 A2 BR112014006222 A2 BR 112014006222A2 BR 112014006222 A BR112014006222 A BR 112014006222A BR 112014006222 A BR112014006222 A BR 112014006222A BR 112014006222 A2 BR112014006222 A2 BR 112014006222A2
Authority
BR
Brazil
Prior art keywords
intestinal
drug
conjugate
diseases
relates
Prior art date
Application number
BR112014006222A
Other languages
English (en)
Inventor
F Arnett John
Davidson Michael
Rongen Roelof
Elshani Sadik
Original Assignee
Davidson Lopez Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Davidson Lopez Llc filed Critical Davidson Lopez Llc
Publication of BR112014006222A2 publication Critical patent/BR112014006222A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract plant steroids and uses thereof [0116] the invention relates to a drug conjugate including a drug and a plant steroid. the drug conjugate may target the drug for intestinal cell delivery, and thus may be used to treat diseases, including intestinal diseases, or to affect intestinal metabolism. the invention therefore also relates to treating intestinal diseases and affecting intestinal metabolism with the drug conjugate. ******************************************************** tradução do resumo resumo patente de invenção: "esteroides vegetais e usos dos mesmos". a presente invenção refere-se a um conjugado medicamentoso incluindo uma droga e um esteroide vegetal. o conjugado medicamentoso pode vetorizar a droga para distribuição nas células intestinais, e portanto pode ser usado para tratar doenças, que incluem doenças intestinais, ou para afetar o metabolismo intestinal. a invenção portanto também se refere ao tratamento de doenças intestinais e à afetação do metabolismo intestinal com o cojugado medicamentoso.
BR112014006222A 2011-09-16 2012-09-14 esteroides vegetais e usos dos mesmos BR112014006222A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535661P 2011-09-16 2011-09-16
US201261675966P 2012-07-26 2012-07-26
PCT/US2012/055549 WO2013040441A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Publications (1)

Publication Number Publication Date
BR112014006222A2 true BR112014006222A2 (pt) 2017-04-11

Family

ID=47883793

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006222A BR112014006222A2 (pt) 2011-09-16 2012-09-14 esteroides vegetais e usos dos mesmos

Country Status (15)

Country Link
US (2) US10086082B2 (pt)
EP (1) EP2755660B1 (pt)
JP (2) JP6035338B2 (pt)
KR (1) KR20140093661A (pt)
CN (2) CN103987390A (pt)
AU (1) AU2012308332A1 (pt)
BR (1) BR112014006222A2 (pt)
CA (1) CA2848979C (pt)
EA (1) EA201490637A1 (pt)
HK (1) HK1200358A1 (pt)
IL (1) IL231541A0 (pt)
IN (1) IN2014CN02688A (pt)
MX (1) MX2014003260A (pt)
SG (1) SG11201400652UA (pt)
WO (1) WO2013040441A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014225743A1 (en) 2013-03-08 2015-09-24 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
KR20150125663A (ko) * 2013-03-08 2015-11-09 알러간, 인코포레이티드 사이클로스포린 a 스테로이드 켤레물
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR102139678B1 (ko) * 2017-11-24 2020-07-31 전북대학교 산학협력단 N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물
CN110051674A (zh) * 2018-07-26 2019-07-26 中国人民解放军空军军医大学第一附属医院 豆甾醇在制备治疗胃癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052029A1 (en) 1999-03-04 2000-09-08 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same
PT1189924E (pt) * 1999-06-23 2004-12-31 Forbes Medi Tech Inc Conjugados de fitosterol ou fitostanol com acido ascorbico e sua utilizacao no tratamento ou prevencao de doenca cardiovascular
WO2002072035A2 (en) * 2001-03-14 2002-09-19 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
CN1531436A (zh) 2001-05-09 2004-09-22 (株)美大富历寿 用于增强粘膜吸收的两亲肝素衍生物制剂
SE0103765D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
US20040236125A1 (en) * 2002-09-25 2004-11-25 Forbes Medi-Tech Inc. Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
WO2004095926A2 (en) * 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
US20050234025A1 (en) * 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
EP2081949B1 (en) 2006-09-22 2014-12-10 GE Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
JP2010509355A (ja) * 2006-11-06 2010-03-25 ジャイナ ファーマシューティカルズ，インコーポレーテッド グッグルリン脂質の方法および組成物
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2011109472A1 (en) 2010-03-02 2011-09-09 Imagenetix, Inc. Compositions comprising myristic acid and uses thereof

Also Published As

Publication number Publication date
EA201490637A1 (ru) 2014-11-28
EP2755660A4 (en) 2015-03-18
JP6035338B2 (ja) 2016-11-30
CA2848979A1 (en) 2013-03-21
CA2848979C (en) 2019-11-05
SG11201400652UA (en) 2014-09-26
JP2017019871A (ja) 2017-01-26
US10086082B2 (en) 2018-10-02
CN103987390A (zh) 2014-08-13
IL231541A0 (en) 2014-04-30
AU2012308332A1 (en) 2014-04-10
EP2755660B1 (en) 2019-11-06
WO2013040441A1 (en) 2013-03-21
US20190083632A1 (en) 2019-03-21
MX2014003260A (es) 2014-09-08
US20150141390A1 (en) 2015-05-21
KR20140093661A (ko) 2014-07-28
CN109384825A (zh) 2019-02-26
HK1200358A1 (en) 2015-08-07
IN2014CN02688A (pt) 2015-07-03
EP2755660A1 (en) 2014-07-23
JP2014526515A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
BR112014006222A2 (pt) esteroides vegetais e usos dos mesmos
Liang et al. Protective roles and mechanisms of Dendrobium officinal polysaccharides on secondary liver injury in acute colitis
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
Gao et al. Shuang-Huang-Lian exerts anti-inflammatory and anti-oxidative activities in lipopolysaccharide-stimulated murine alveolar macrophages
Huang et al. Shikonin inhibits oxidized LDL-induced monocyte adhesion by suppressing NFκB activation via up-regulation of PI3K/Akt/Nrf2-dependent antioxidation in EA. hy926 endothelial cells
Xin et al. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats
Lu et al. Tanshinone IIA improves depression-like behavior in mice by activating the ERK-CREB-BDNF signaling pathway
Reisman et al. Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
Wang et al. Ginsenoside Rg1 reduces aldosterone-induced autophagy via the AMPK/mTOR pathway in NRK-52E cells
Tong et al. Astragalin exerted antidepressant-like action through SIRT1 signaling modulated NLRP3 inflammasome deactivation
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
Meng et al. Ursolic acid protects hepatocytes against lipotoxicity through activating autophagy via an AMPK pathway
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
Zhang et al. Evaluating the effects of mitochondrial autophagy flux on ginsenoside Rg2 for delaying D-galactose induced brain aging in mice
BR112013023970A2 (pt) composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares
BR112014005398A2 (pt) peptídeo que inibe a atividade de metaloproteinases de matriz e uso do mesmo
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
Lu et al. Curcumin promotes neurite outgrowth via reggie-1/flotillin-2 in cortical neurons
Zhu et al. Mechanism and regulation of mitophagy in nonalcoholic fatty liver disease (NAFLD): A mini-review
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
Zhang et al. The potent anti-inflammatory agent escin does not increase corticosterone secretion and immune cell apoptosis in mice

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI